NEW YORK (GenomeWeb) – Veracyte announced today that it has priced a public offering of 5 million shares of its common stock at $6 per share, for gross proceeds of $30 million.

The offering’s underwriters have also been granted a 30-day option to buy an additional 750,000 shares at the public offering price, minus underwriting discounts and commissions.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.